CS
BHVN

Candriam SCA’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Candriam SCA’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-144,428
Closed -$21M – 915
2022
Q2 		$21M Buy
+144,428
New +$18.4M 0.17% 131
2021
Q4 		– Sell
-47,005
Closed -$6.53M – 925
2021
Q3 		$6.53M Hold
47,005
– – 0.04% 346
2021
Q2 		$4.56M Sell
47,005
-2,062
-4% -$167K 0.03% 422
2021
Q1 		$4.04M Hold
49,067
– – 0.03% 410
2020
Q4 		$4.21M Sell
49,067
-107,820
-69% -$9.14M 0.03% 421
2020
Q3 		$10.2M Sell
156,887
-15,912
-9% -$1.04M 0.1% 230
2020
Q2 		$12.6M Sell
172,799
-16,000
-8% -$851K 0.13% 179
2020
Q1 		$10M Hold
188,799
– – 0.11% 211
2019
Q4 		$10.3M Sell
188,799
-231,000
-55% -$11.4M 0.11% 213
2019
Q3 		$17.5M Sell
419,799
-38,000
-8% -$1.61M 0.23% 94
2019
Q2 		$20M Buy
457,799
+15,000
+3% +$846K 0.25% 90
2019
Q1 		$22.8M Sell
442,799
-105,000
-19% -$4.54M 0.29% 77
2018
Q4 		$20.3M Buy
547,799
+130,500
+31% +$4.71M 0.31% 64
2018
Q3 		$15.7M Buy
417,299
+210,200
+101% +$7.73M 0.21% 115
2018
Q2 		$8.19M Buy
207,099
+102,099
+97% +$3.24M 0.13% 202
2018
Q1 		$2.71M Buy
105,000
+25,000
+31% +$747K 0.05% 414
2017
Q4 		$2.16M Buy
+80,000
New +$2.2M 0.04% 435

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Candriam SCA's BHVN Position: Q3 2022 in Review

Candriam SCA sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 144,428 shares — an estimated $21M sold.

Candriam SCA first reported a position in BHVN in Q4 2017 and held it in 17 quarters. The position peaked at $22.8M in Q1 2019. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Candriam SCA reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Candriam SCA sold 144,428 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $21M.
  • Candriam SCA first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 17 quarters.
  • Candriam SCA's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $22.8M in Q1 2019.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.